1-866-598-7166

A Study of MK-4700 Alone or With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

Trial ID: NCT06894771
Kidney Cancer Type: Clear cell or papillary


Background:

MK-4700 is an investigational drug being studied for its safety, tolerability, and potential anti-cancer effects. It is being tested in combination with other cancer therapies.

Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works by targeting a molecule called PD-1 to reactivate the body’s own immune response to target and destroy cancer cells.

Since this drug is still in the clinical trial phase, it has the placeholder name MK-4700 rather than a commercial trade name.


The Trial:

This study will investigate safety and effectiveness as an anti-cancer drug of MK-4700, alone, or in combination with Pembrolizumab in patients with advanced malignant kidney cancer.

Kidney cancer participants will be sequentially assigned to one of the below treatment regimes:

  • MK-4700 alone
  • MK-4700 + Pembrolizumab


Basic Eligibility:

  • Clear cell or papillary subtype kidney cancer
  • Advanced or metastatic solid tumor
  • already tried treatment, but it either stopped working or caused serious side effects

 

Additional eligibility criteria will apply. Please speak to your doctor.

Find out more about this study.
Hospital / Cancer CentrePrincipal InvestigatorLocationTrial Status
Hospital / Cancer CentrePrincess Margaret Cancer Centre Principal InvestigatorNot Given LocationToronto, ON Trial StatusRecruiting
Hospital / Cancer CentreCHU de Québec Université Laval, Hôpital de l'Enfant-Jésus Principal InvestigatorNot Given LocationQuebec, QC Trial StatusRecruiting
Kidney Cancer Canada